The newly launched Prevention Suite from Esaote
is a unique package of ultrasound imaging modalities for both cardiac and
vascular investigations and is designed to provide clinicians with a wide range
of tools for assessing a patient’s risk of cardiovascular disease quickly and
reliably, often before symptoms occur. The four advanced technologies that make
up Prevention Suite are CFI, XStrain, QIMT and QAS which, respectively, measure coronary flow
quantification, cardiac deformation indexes, carotid intima-media thickness and
arterial stiffness,. The vascular measurements are performed using RF signal
analysis which provides high spatial resolution for greater accuracy.
“For clinicians — from GPs to Cardiologists —
Prevention Suite is a unique and technically superb ‘one-stop-shop’ for
cardiovascular assessment. It allows us to quickly and reliably make an
appraisal of the patient, providing information about the actual biological
risk of atherosclerosis. The resolution for vessel analysis is particularly
impressive. There is no equivalent that allows us this multiplicity of
information in the pre-clinical phase. Patients are fascinated by the
examination too, and Prevention Suite’s real-life images are highly persuasive
in convincing them to modify their lifestyle.” Professor Cristina Giannattasio,
Head Cardiology IV, Cardiologic Department at Niguarda Hospital, Milan, also
notes, “Atherosclerosis is one of the pathologies which can remain asymptomatic
for a long time. The availability of dedicated cardiac and vascular
measurements in the same device offers a more user-friendly and comprehensive
assessment with the benefit of being able to detect early risk of CV
disease.” She adds, “In the future,
preventative approaches will be the best way of reducing morbidity and
mortality.”
Ongoing clinical studies involving hundreds of
patients at clinical centres throughout Europe have started to show the
benefits of a preventative screening approach. Professor Rigo explains, “The
integration of cardiac and vascular assessments will help physicians identify
the actual biological risk of atherosclerosis. Once the clinical risk is identified, clinicians can
work with patients on early intervention strategies and lifestyle modification
before the risk of CVD escalates.
Esaote
Genoa,
Italy